Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma
Abstract
Mantle cell lymphoma (MCL) is an aggressive malignancy that is characterized by poor prognosis. Large-scale pharmacological profiling across more than 100 hematological cell line models identified a subset of MCL cell lines that are highly sensitive to the B cell receptor (BCR) signaling inhibitors ibrutinib and sotrastaurin. Sensitive MCL models exhibited chronic activation of the BCR-driven classical nuclear factor-κB (NF-κB) pathway, whereas insensitive cell lines displayed activation of the alternative NF-κB pathway. Transcriptome sequencing revealed genetic lesions in alternative NF-κB pathway signaling components in ibrutinib-insensitive cell lines, and sequencing of 165 samples from patients with MCL identified recurrent mutations in TRAF2 or BIRC3 in 15% of these individuals. Although they are associated with insensitivity to ibrutinib, lesions in the alternative NF-κB pathway conferred dependence on the protein kinase NIK (also called mitogen-activated protein 3 kinase 14 or MAP3K14) both in vitro and in vivo. Thus, NIK is a new therapeutic target for MCL treatment, particularly for lymphomas that are refractory to BCR pathway inhibitors. Our findings reveal a pattern of mutually exclusive activation of the BCR-NF-κB or NIK-NF-κB pathways in MCL and provide critical insights into patient stratification strategies for NF-κB pathway-targeted agents.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Roughly one-third of patients with MCL fail to respond to ibrutinib (intrinsic resistance).
“roughly one-third of patients with MCL fail to respond to ibrutinib (intrinsic resistance)”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [7]
Intrinsic ibrutinib resistance in MCL may be due in part to activation of nonclassical NF-kB signaling.
“which may be due in part to activation of nonclassical NF-kB signaling.7”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [7]
The NF-kB pathway is critical in MCL cells.
“As the NF-kB pathway is critical in MCL cells, 7”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [7]
There are multiple mechanisms through which a lymphoma cell may be resistant to BTK degraders, including reduced uptake, increased efflux, mutations of BTK that block binding, activating mutations in PLCg2 or alternative NF-kB, or alterations that affect E3 ligase/proteasome function.
“Third, there are multiple mechanisms through which a lymphoma cell may be resistant to BTK degraders, including reduced uptake, increased efflux, mutations of BTK that block binding, activating mutations in PLCg2 or alternative NF-kB, 7 or alterations that affect E3 ligase/proteasome function.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [7]
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · see citing works
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556 · see citing works
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816 · see citing works
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,477 · see citing works
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,216 · see citing works
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · see citing works
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works
Self-citationAn integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711 · see citing works
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,822 · see citing works
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679 · see citing works
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · see citing works
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685 · see citing works
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651 · see citing works
Self-citationHonigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561 · see citing works
Activation by IKKα of a Second, Evolutionary Conserved, NF-κB Signaling Pathway
Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Krähn, G. M., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., Sun, S., et al. (2001) · Science · doi:10.1126/science.1062677 · Cited by 1,361 · see citing works
MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1
Malinin, N. L., Boldin, M., Kovalenko, A. V., & Wallach, D. (1997) · Nature · doi:10.1038/385540a0 · Cited by 1,279 · see citing works
Chen, Z., Hagler, J., Palombella, V. J., Melandri, F. D., Scherer, D. C., Ballard, D. W., & Maniatis, T. (1995) · Genes & Development · doi:10.1101/gad.9.13.1586 · Cited by 1,270 · see citing works
Annunziata, C. M., Davis, R. E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.004 · Cited by 952 · see citing works
Self-citationThe Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways
Dejardin, E., Droin, N. M., Delhase, M., Haas, E., Cao, Y., Makris, C., Li, Z., Karin, M., Ware, C. F., & Green, D. R. (2002) · Immunity · doi:10.1016/s1074-7613(02)00423-5 · Cited by 923 · see citing works
Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
Lenz, G., Davis, R., Ngo, V. N., Lam, L., George, T., Wright, G., Dave, S., Zhao, H., Xu, W.-H., Rosenwald, A., et al. (2008) · Science · doi:10.1126/science.1153629 · Cited by 896 · see citing works
Self-citationBAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells
Claudio, E., Brown, K., Park, S., Wang, H., & Siebenlist, U. K. (2002) · Nature Immunology · doi:10.1038/ni842 · Cited by 694 · see citing works
Coupling of a Signal Response Domain in IκBα to Multiple Pathways for NF-κB Activation
Brockman, J. A., Scherer, D. C., McKinsey, T. A., Hall, S. M., Qi, X., Lee, W. Y., & Ballard, D. W. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2809 · Cited by 684 · see citing works
Zarnegar, B. J., Wang, Y., Mahoney, D. J., Dempsey, P. W., Cheung, H. H., He, J., Shiba, T. L., Yang, X., Yeh, W., Mak, T. W., et al. (2008) · Nature Immunology · doi:10.1038/ni.1676 · Cited by 607 · see citing works
A loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H. G., Lenz, G., Lam, L. T., Davé, S. S., Yang, L., Powell, J. I., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 606 · see citing works
Self-citationVallabhapurapu, S., Matsuzawa, A., Zhang, W., Tseng, P., Keats, J. J., Wang, H., Vignali, D. A. A., Bergsagel, P. L., & Karin, M. (2008) · Nature Immunology · doi:10.1038/ni.1678 · Cited by 605 · see citing works
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A. T., Miller, C., deBeaumont, R. S., Stegmeier, F. P., Yao, Y.-M., & Christoph Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545 · see citing works
Self-citationNF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176
Lei, L., Cao, Z., & Goeddel, D. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3792 · Cited by 536 · see citing works
Liao, G., Zhang, M., Harhaj, E. W., & Sun, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403286200 · Cited by 467 · see citing works
Single-vector inducible lentiviral RNAi system for oncology target validation
Wiederschain, D., Susan, W. N., Chen, L., Loo, A. T., Yang, G., Huang, A., Chen, Y., Caponigro, G., Yao, Y.-M., Christoph Lengauer, C., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7701 · Cited by 441 · see citing works
Self-citationLam, L. T., Wright, G. W., Davis, R. E., Lenz, G., Farinha, P., Dang, L., Chan, J. W., Rosenwald, A., Gascoyne, R. D., & Staudt, L. M. (2007) · Blood · doi:10.1182/blood-2007-09-111948 · Cited by 355 · see citing works
Self-citationLam, L. T., Davis, R. E., Pierce, J., Hepperle, M. E., Xu, Y., Foley, M. H., Nong, Y., Wen, D., Adams, J., Dang, L., et al. (2005) · PubMed · Cited by 312 · see citing works
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Demchenko, Y. N., Glebov, O. K., Zingone, A., Keats, J. J., Bergsagel, P. L., & Kuehl, W. M. (2010) · Blood · doi:10.1182/blood-2009-09-243535 · Cited by 289 · see citing works
Pfeifer, M., Grau, M., Lenze, D., Wenzel, S.-S., Wolf, A., Wollert‐Wulf, B., Dietze, K., Nogai, H., Storek, B., Madle, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305656110 · Cited by 270 · see citing works
Self-citationNatural genetic variation caused by small insertions and deletions in the human genomePreprint
Mills, R. E., Pittard, W. S., Mullaney, J. M., Farooq, U., Creasy, T. H., Mahurkar, A., Kemeza, D. M., Strassler, D. S., Ponting, C. P., Webber, C., et al. (2011) · Genome Research · doi:10.1101/gr.115907.110 · Cited by 264 · see citing works
Hailfinger, S., Nogai, H., Pelzer, C., Jaworski, M., Cabalzar, K., Charton, J. E., Guzzardi, M., Décaillet, C., Grau, M., Dörken, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105020108 · Cited by 241 · see citing works
Self-citationAntigen Receptor Signaling to NF- B via CARMA1, BCL10, and MALT1Preprint
Thome, M., Charton, J. E., Pelzer, C., & Hailfinger, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003004 · Cited by 241 · see citing works
Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases
Lam, J. S., Yamashiro, J., Shintaku, I. P., Vessella, R. L., Jenkins, R. B., Horvath, S., Said, J. W., & Reiter, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1842 · Cited by 211 · see citing works
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma
Hailfinger, S., Lenz, G., Ngo, V. N., Posevitz‐Fejfár, A., Rebeaud, F., Guzzardi, M., Penas, E. M. M., Dierlamm, J., Chan, W. C., Staudt, L. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907511106 · Cited by 204 · see citing works
Self-citationControl of canonical NF-κB activation through the NIK–IKK complex pathway
Zarnegar, B. J., Yamazaki, S., He, J. Q., & Cheng, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707959105 · Cited by 183 · see citing works
How I treat mantle cell lymphoma
Ghielmini, M. E. G., & Zucca, E. (2009) · Blood · doi:10.1182/blood-2009-02-179739 · Cited by 182 · see citing works
A critical role for the NFkB pathway in multiple myeloma
Demchenko, Y. N., & Kuehl, W. M. (2010) · Oncotarget · doi:10.18632/oncotarget.109 · Cited by 176 · see citing works
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management
Jabbour, E. J., & Kantarjian, H. M. (2012) · American Journal of Hematology · doi:10.1002/ajh.23282 · Cited by 144 · see citing works
Wagner, J., von Matt, P., Sedrani, R. C., Albert, R., Cooke, N. G., Ehrhardt, C., Geiser, M., Rummel, G., Stark, W., Strauss, A., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901108b · Cited by 132 · see citing works
Naylor, T. L., Tang, H., Ratsch, B. A., Enns, A., Loo, A. T., Chen, L., Lenz, P., Waters, N. J., Schüler, W., Dörken, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2525 · Cited by 119 · see citing works
Self-citationIκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL
Nogai, H., Wenzel, S.-S., Hailfinger, S., Grau, M., Kaergel, E., Seitz, V., Wollert‐Wulf, B., Pfeifer, M., Wolf, A., Frick, M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-508028 · Cited by 83 · see citing works
Self-citationHodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival
Ranuncolo, S. M., Pittaluga, S., Evbuomwan, M. O., Jaffe, E. S., & Lewis, B. A. (2012) · Blood · doi:10.1182/blood-2012-01-405951 · Cited by 76 · see citing works
Wagner, J., von Matt, P., Faller, B., Cooke, N. G., Albert, R., Sedrani, R. C., Wiegand, H., Jean, C., Beerli, C., Weckbecker, G., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200469u · Cited by 40 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3702 · Cited by 564 · see citing works
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507 · see citing works
Self-citationIbrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, C. S. L., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S. M., Hicks, R. J., Burbury, K., Turner, G. E., Iulio, J. D., Bressel, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715519 · Cited by 429 · see citing works
Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M. K., Kolstad, A., Pedersen, L. B., Montano‐Almendras, C. P., Husby, S., Freiburghaus, C., Ek, S., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779736 · Cited by 414 · see citing works
Predicting HLA class II antigen presentation through integrated deep learning
Chen, B., Khodadoust, M. S., Olsson, N., Wagar, L. E., Fast, E., Liu, C. L., Muftuoglu, Y., Sworder, B. J., Diehn, M., Levy, R., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0280-2 · Cited by 317 · see citing works
Postibrutinib outcomes in patients with mantle cell lymphoma
Martin, P., Maddocks, K. J., Leonard, J. P., Ruan, J., Goy, A. H., Wagner‐Johnston, N. D., Rule, S. A., Advani, R. H., Iberri, D. J., Phillips, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-10-673145 · Cited by 298 · see citing works
Recurrent mutations refine prognosis in chronic lymphocytic leukemia
Baliakas, P., Hadzidimitriou, A., Sutton, L.-A., Rossi, D., Minga, E., Villamor, N., Larráyoz, M., Kmínková, J., Agathangelidis, A., Davis, Z. A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.196 · Cited by 287 · see citing works
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Jain, P., & Wang, M. L. (2019) · American Journal of Hematology · doi:10.1002/ajh.25487 · Cited by 277 · see citing works
Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0098 · Cited by 273 · see citing works
Zhang, J., Jima, D. D., Moffitt, A. B., Liu, Q., Czader, M., Hsi, E. D., Fedoriw, Y. D., Dunphy, C. H., Richards, K. L., Gill, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-517177 · Cited by 237 · see citing works
Zhang, L., Yao, Y., Zhang, S., Liu, Y., Guo, H., Ahmed, M., Bell, T., Zhang, H., Han, G., Lorence, E., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau1167 · Cited by 233 · see citing works
Second-generation inhibitors of Bruton tyrosine kinase
Wu, J., Liu, C., Tsui, S. T., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0313-y · Cited by 216 · see citing works
Agarwal, R., Chan, Y.-C., Tam, C. S. L., Hunter, T., Vassiliadis, D., Teh, C. E., Thijssen, R., Yeh, P. S.-H., Wong, S. Q., Ftouni, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0243-z · Cited by 204 · see citing works
The RING finger protein family in health and disease
Cai, C., Tang, Y., Zhai, J., & Zheng, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01152-2 · Cited by 194 · see citing works
BIRC3 and BIRC5: multi‐faceted inhibitors in cancer
Frazzi, R. (2021) · Cell & Bioscience · doi:10.1186/s13578-020-00521-0 · Cited by 190 · see citing works
Sun, B., Fiskus, W. C., Qian, Y., Rajapakshe, K., Raina, K., Coleman, K. G., Crew, A. P. A., Shen, A., Saenz, D. T., Mill, C. P., et al. (2017) · Leukemia · doi:10.1038/leu.2017.207 · Cited by 181 · see citing works
Mantle cell lymphoma: evolving management strategies
Campo, E., & Rule, S. A. (2014) · Blood · doi:10.1182/blood-2014-05-521898 · Cited by 174 · see citing works
Genomic profiling for clinical decision making in lymphoid neoplasms
de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A. J., Doǧan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., et al. (2022) · Blood · doi:10.1182/blood.2022015854 · Cited by 171 · see citing works
Self-citationBruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169 · see citing works
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
Saba, N. S., Liu, D., Herman, S. E. M., Underbayev, C., Tian, X., Behrend, D., Weniger, M. A., Skarzynski, M., Gyamfi, J., Fontán, L., et al. (2016) · Blood · doi:10.1182/blood-2015-11-681460 · Cited by 164 · see citing works
Targeting NF-κB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer
Pflug, K. M., & Sitcheran, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228470 · Cited by 163 · see citing works
Alu, A., Lei, H., Han, X., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01353-w · Cited by 157 · see citing works
Roit, F. D., Engelberts, P. J., Taylor, R. P., Breij, E. C. W., Gritti, G., Rambaldi, A., Introna, M., Parren, P. W. H. I., Beurskens, F. J. M., & Golay, J. (2014) · Haematologica · doi:10.3324/haematol.2014.107011 · Cited by 150 · see citing works
Drug-perturbation-based stratification of blood cancer
Dietrich, S., Oleś, M., Lu, J., Sellner, L., Anders, S., Velten, B., Wu, B., Hüllein, J., Liberio, M. D. S., Walther, T., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93801 · Cited by 147 · see citing works
Pathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment
Young, R. M., Phelan, J. D., Wilson, W. H., & Staudt, L. M. (2019) · Immunological Reviews · doi:10.1111/imr.12792 · Cited by 145 · see citing works
Wu, C., de Miranda, N. F. C. C., Chen, L., Wasik, A. M., Mansouri, L., Jurczak, W. J., Gałązka, K., Długosz‐Danecka, M., Machaczka, M., Zhang, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9500 · Cited by 138 · see citing works
Ferrero, S., Rossi, D., Rinaldi, A., Bruscaggin, A., Spina, V., Eskelund, C. W., Evangelista, A., Moia, R., Kwee, I., Dahl, C., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.214056 · Cited by 137 · see citing works
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis
Hill, H. A., Qi, X., Jain, P., Nomie, K. J., Wang, Y., Zhou, S., & Wang, M. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001350 · Cited by 132 · see citing works
Gouill, S. L., Morschhauser, F., Chiron, D., Bouabdallah, K. K., Cartron, G., Casasnovas, O., Bodet‐Milin, C., Ragot, S., Bossard, C., Nadal, N., et al. (2020) · Blood · doi:10.1182/blood.2020008727 · Cited by 130 · see citing works
Knittel, G., Liedgens, P., Korovkina, D., Seeger, J. M., Al-Baldawi, Y., Al-Maarri, M., Fritz, C., Vlantis, K., Bezhanova, S. D., Scheel, A. H., et al. (2016) · Blood · doi:10.1182/blood-2015-11-684183 · Cited by 120 · see citing works
Jain, P., Kanagal‐Shamanna, R., Zhang, S., Ahmed, M., Ghorab, A., Zhang, L., Ok, C. Y., Li, S., Hagemeister, F. B., Zeng, D., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15567 · Cited by 121 · see citing works
Elvers, I., Turner-Maier, J., Swofford, R., Koltookian, M., Johnson, J., Stewart, C., Zhang, C.-Z., Schumacher, S. E., Beroukhim, R., Rosenberg, M. W., et al. (2015) · Genome Research · doi:10.1101/gr.194449.115 · Cited by 119 · see citing works
Jayappa, K. D., Portell, C. A., Gordon, V. L., Capaldo, B. J., Bekiranov, S., Axelrod, M. J., Brett, L. K., Wulfkuhle, J. D., Gallagher, R. I., Petricoin, E. F., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016004176 · Cited by 116 · see citing works
Puente, X. S., Jares, P., & Campo, E. (2018) · Blood · doi:10.1182/blood-2017-10-764373 · Cited by 111 · see citing works
The paracaspase MALT1: biological function and potential for therapeutic inhibition
Jaworski, M., & Thome, M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2059-z · Cited by 109 · see citing works
Drug-perturbation-based stratification of blood cancer
Dietrich, S., Oleś, M., Lu, J., Sellner, L., Anders, S., Velten, B., Wu, B., Hüllein, J., Libério, M. S., Walther, T., et al. (2017) · Kölner Universitäts PublikationsServer (Universität zu Köln) · doi:10.17863/cam.20903 · Cited by 111 · see citing works
Sun, B., Shah, B., Fiskus, W. C., Qi, J., Rajapakshe, K., Coarfa, C., Li, L., Devaraj, S. G. T., Sharma, S., Zhang, L., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639542 · Cited by 105 · see citing works
Nakhoda, S., Vistarop, A., & Wang, Y. L. (2023) · British Journal of Haematology · doi:10.1111/bjh.18418 · Cited by 104 · see citing works
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
George, B., Chowdhury, S. M., Hart, A., Sircar, A., Singh, S. K., Nath, U. K., Mamgain, M., Singhal, N. K., Sehgal, L., & Jain, N. K. (2020) · Cancers · doi:10.3390/cancers12051328 · Cited by 96 · see citing works
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
Hershkovitz‐Rokah, O., Pulver, D., Lenz, G., & Shpilberg, O. (2018) · British Journal of Haematology · doi:10.1111/bjh.15108 · Cited by 100 · see citing works
Self-citationPhosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
Kikuchi, J., Koyama, D., Wada, T., Izumi, T., Hofgaard, P. O., Bogen, B., & Furukawa, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80325 · Cited by 97 · see citing works
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
Chiron, D., Bellanger, C., Papin, A., Tessoulin, B., Dousset, C., Maïga, S., Moreau, A., Esbelin, J., Trichet, V., Chen‐Kiang, S., et al. (2016) · Blood · doi:10.1182/blood-2016-06-720490 · Cited by 98 · see citing works
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma
Yang, Y., Kelly, P. N., Shaffer, A. L., Schmitz, R., Yoo, H. M., Liu, X., Huang, D. W., Webster, D. E., Young, R. M., Nakagawa, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.006 · Cited by 96 · see citing works
Self-citationGenetic Alterations of TRAF Proteins in Human Cancers
Zhu, S., Jin, J., Gokhale, S., Lu, A. M., Shan, H., Feng, J., & Xie, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02111 · Cited by 94 · see citing works
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
Diop, F., Moia, R., Favini, C., Spaccarotella, E., Paoli, L. D., Bruscaggin, A., Spina, V., di Bergamo, L. T., Arruga, F., Tarantelli, C., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219550 · Cited by 92 · see citing works
Matrix Metalloproteinase 2 Is Required for Ovulation and Corpus Luteum Formation in Drosophila
Deady, L. D., Shen, W., Mosure, S. A., Spradling, A. C., & Sun, J. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1004989 · Cited by 90 · see citing works
Precision therapy for lymphoma—current state and future directions
Intlekofer, A. M., & Younes, A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.137 · Cited by 88 · see citing works
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
Zhang, S. Y., Smith, S. M., Zhang, S. Y., & Wang, Y. L. (2015) · British Journal of Haematology · doi:10.1111/bjh.13427 · Cited by 88 · see citing works
Holding All the CARDs: How MALT1 Controls CARMA/CARD-Dependent Signaling
Juilland, M., & Thome, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01927 · Cited by 88 · see citing works
Dynamic aberrant NF-κB spurs tumorigenesis: A new model encompassing the microenvironment
Vlahopoulos, S., Çen, O., Hengen, N., AGAN, J. E., Moschovi, M. A., Critselis, E., Adamaki, M., Bacopoulou, F., Copland, J. A., Boldogh, I. R., et al. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.06.001 · Cited by 87 · see citing works
NF-κB in the New Era of Cancer Therapy.
Eluard, B., Thieblemont, C., & Baud, V. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.04.003 · Cited by 74 · see citing works
A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes
Zhou, Q., Derti, A., Ruddy, D. A., Rakiec, D. P., Kao, I., Lira, M., Gibaja, V., Chan, H., Yang, Y., Min, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2930 · Cited by 81 · see citing works
Self-citationYi, S., Yan, Y., Jin, M., Bhattacharya, S., Wang, Y., Wu, Y., Yang, L., Gine, E., Clot, G., Chen, L., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153283 · Cited by 87 · see citing works
TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer
Siegmund, D., Wagner, J., & Wajant, H. (2022) · Cancers · doi:10.3390/cancers14164055 · Cited by 81 · see citing works
Papin, A., Tessoulin, B., Bellanger, C., Moreau, A., Bris, Y. L., Maisonneuve, H., Moreau, P., Touzeau, C., Amiot, M., Pellat‐Deceunynck, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0463-3 · Cited by 80 · see citing works
Efremov, D. G., Turkalj, S., & Laurenti, L. (2020) · Cancers · doi:10.3390/cancers12061396 · Cited by 78 · see citing works
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
Balaji, S., Ahmed, M., Lorence, E., Yan, F., Nomie, K. J., & Wang, M. L. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0621-5 · Cited by 77 · see citing works
Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies
Juilland, M., & Thome, M. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000257 · Cited by 76 · see citing works
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies
Ondrišová, L., & Mráz, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.591577 · Cited by 76 · see citing works
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
Ran, F., Liu, Y., Wang, C., Xu, Z., Zhang, Y., Liu, Y., Zhao, G., & Ling, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114009 · Cited by 74 · see citing works
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
Mohanty, A. R., Sandoval, N., Das, M., Pillai, R. K., Chen, L., Chen, R. W., Amin, H. M., Wang, M. L., Marcucci, G., Weisenburger, D. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12434 · Cited by 74 · see citing works
Therapeutic options for relapsed/refractory mantle cell lymphoma
Eyre, T. A., Cheah, C. Y., & Wang, M. L. (2021) · Blood · doi:10.1182/blood.2021013326 · Cited by 75 · see citing works
B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma
Dai, B., Grau, M., Juilland, M., Klener, P., Höring, E., Molinský, J., Schimmack, G., Aukema, S., Hoster, E., Vogt, N., et al. (2016) · Blood · doi:10.1182/blood-2016-05-718775 · Cited by 70 · see citing works
Self-citationEpperla, N., Hamadani, M., Cashen, A. F., Ahn, K. W., Oak, E., Kanate, A. S., Calzada, O., Cohen, J. B., Farmer, L., Ghosh, N., et al. (2017) · Hematological Oncology · doi:10.1002/hon.2380 · Cited by 71 · see citing works
Huse, K., Bai, B., Hilden, V. I., Bollum, L. K., Våtsveen, T. K., Munthe, L. A., Smeland, E. B., Irish, J. M., Wälchli, S., & Myklebust, J. H. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200144 · Cited by 69 · see citing works
Yi, S., Yan, Y., Jin, M., Bhattacharya, S., Wang, Y., Wu, Y., Yang, L., Giné, E., Clot, G., Chen, L., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 69 · see citing works
Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy
Pitter, K. L., Casey, D. L., Lu, Y. C., Hannum, M., Zhang, Z., Song, X., Pecorari, I. L., McMillan, B., Ma, J., Samstein, R. M., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa095 · Cited by 69 · see citing works
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
Li, Y.-Q., Bouchlaka, M. N., Wolff, J., Grindle, K. M., Lu, L., Qian, S., Zhong, X., Pflum, N., Jobin, P., Kahl, B. S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.155 · Cited by 67 · see citing works
Genetic landscape and deregulated pathways in B‐cell lymphoid malignancies
Rosenquist, R., Beà, S., Du, M., Nadel, B., & Pan‐Hammarström, Q. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12633 · Cited by 66 · see citing works
Lee, J., Zhang, L. L., Wu, W., Guo, H., Li, Y., SUKHANOVA, M. J., Venkataraman, G., Huang, S., Zhang, H., Alikhan, M. B., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016048 · Cited by 64 · see citing works
Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma
Furukawa, Y., & Kikuchi, J. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2048-5 · Cited by 63 · see citing works
NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy
Grondona, P., Bucher, P., Schulze‐Osthoff, K., Hailfinger, S., & Schmitt, A. (2018) · Biomedicines · doi:10.3390/biomedicines6020038 · Cited by 62 · see citing works
IKK/Nuclear Factor-kappaB and Oncogenesis
Bradford, J. W., & Baldwin, A. S. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00003-2 · Cited by 58 · see citing works
Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches
Silkenstedt, E., Linton, K., & Dreyling, M. H. (2021) · British Journal of Haematology · doi:10.1111/bjh.17419 · Cited by 59 · see citing works
Onaindía, A., Medeiros, L. J., & Patel, K. P. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.58 · Cited by 58 · see citing works
Rudelius, M., Rosenfeldt, M. T., Leich, E., Rauert‐Wunderlich, H., Solimando, A. G., Beilhack, A., Ott, G., & Rosenwald, A. (2017) · Haematologica · doi:10.3324/haematol.2017.177162 · Cited by 55 · see citing works
Lantermann, A. B., Chen, D., McCutcheon, K., Hoffman, G., Frias, E., Ruddy, D. A., Rakiec, D. P., Korn, J. M., McAllister, G., Stegmeier, F. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1113 · Cited by 54 · see citing works
Self-citationEzell, S. A., Mayo, M., Bihani, T., Tepsuporn, S., Wang, S., Passino, M. A., Grosskurth, S. E., Collins, M., Parmentier, J. M., Reimer, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2071 · Cited by 54 · see citing works
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Profitós-Pelejà, N., Santos, J. C., Marín‐Niebla, A., Roué, G., & Ribeiro, M. L. (2022) · Cancers · doi:10.3390/cancers14040860 · Cited by 50 · see citing works
The molecular pathogenesis of mantle cell lymphoma
Vogt, N., Dai, B., Erdmann, T., Berdel, W. E., & Lenz, G. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1248965 · Cited by 51 · see citing works
Self-citationYue, C., Niu, M., Shan, Q. Q., Zhou, T., Tu, Y., Xie, P., Hua, L., Yu, R., & Liu, X. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0600-7 · Cited by 50 · see citing works
Ming, M., Wu, W., Xie, B., SUKHANOVA, M. J., Wang, W., Kadri, S., Sharma, S., Lee, J., Shacham, S., Landesman, Y., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0789-atr · Cited by 50 · see citing works
Kiebala, M., Skalska, J., Casulo, C., Brookes, P. S., Peterson, D. R., Hilchey, S. P., Dai, Y., Grant, S., Maggirwar, S. B., & Bernstein, S. H. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.10.004 · Cited by 48 · see citing works
Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond
Rosenquist, R., Rosenwald, A., Du, M., Gaïdano, G., Groenen, P., Wotherspoon, A. C., Ghia, P., Gaulard, P., Campo, E., & Σταματόπουλος, Κ. (2016) · Haematologica · doi:10.3324/haematol.2015.134510 · Cited by 48 · see citing works
Current overview and treatment of mantle cell lymphoma
Schieber, M., Gordon, L. I., & Karmali, R. (2018) · F1000Research · doi:10.12688/f1000research.14122.1 · Cited by 47 · see citing works
CD79B limits response of diffuse large B cell lymphoma to ibrutinib
Kim, J. H., Kim, W. S., Ryu, K. J., Kim, S. J., & Park, C. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1113276 · Cited by 45 · see citing works
Self-citationRecent advances in understanding the biology of marginal zone lymphoma
Bertoni, F., Rossi, D., & Zucca, E. (2018) · F1000Research · doi:10.12688/f1000research.13826.1 · Cited by 45 · see citing works
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Jacobson, C., Kopp, N., Layer, J. V., Redd, R. A., Tschuri, S., Haebe, S., van Bodegom, D., Bird, L., Christie, A. L., Christodoulou, A., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711176 · Cited by 45 · see citing works
Activity-Based Probes for Detection of Active MALT1 Paracaspase in Immune Cells and Lymphomas
Eitelhuber, A. C., Vosyka, O., Nagel, D., Bognar, M., Lenze, D., Lammens, K., Schlauderer, F., Hlahla, D., Hopfner, K., Lenz, G., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.10.021 · Cited by 44 · see citing works
Self-citationAberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies
Kennedy, R., & Klein, U. (2018) · Cells · doi:10.3390/cells7110189 · Cited by 43 · see citing works
Ibrutinib for the Treatment of Mantle Cell Lymphoma
Herrera, A. F., & Jacobsen, E. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0010 · Cited by 43 · see citing works
NIK as a Druggable Mediator of Tissue Injury
Rivas, L. V., Vaquero, J. J., Sucunza, D., Gutiérrez, S., Sanz, A. B., Fresno, M., Ortíz, A., & Sánchez-Niño, M. D. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.005 · Cited by 42 · see citing works
An overview of healthcare data analytics with applications to the COVID-19 pandemic
Fei, Z., Ryeznik, Y., Sverdlov, A., Tan, C. W., & Wong, W. K. (2021) · IEEE Transactions on Big Data · doi:10.1109/tbdata.2021.3103458 · Cited by 41 · see citing works
The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma
Wang, H., Zhang, W., Yang, J., & Zhou, K. (2021) · Hematological Oncology · doi:10.1002/hon.2933 · Cited by 41 · see citing works
McDonald, G., Chubukov, V., Coco, J., Truskowski, K., Narayanaswamy, R., Choe, S. E., Steadman, M., Artin, E., Padyana, A. K., Jin, L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0550 · Cited by 37 · see citing works
Self-citationFunction and targeting of MALT1 paracaspase in cancer
O’Neill, T. J., Tofaute, M. J., & Krappmann, D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102568 · Cited by 39 · see citing works
Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms
Mouhssine, S., Maher, N., Matti, B. F., Alwan, A., & Gaïdano, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063234 · Cited by 40 · see citing works
Gene mutations and actionable genetic lesions in mantle cell lymphoma
Ahmed, M., Zhang, L. Y., Nomie, K. J., Lam, L. T., & Wang, M. L. (2016) · Oncotarget · doi:10.18632/oncotarget.10716 · Cited by 39 · see citing works
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma
Arkwright, R. T., Pham, T. M., Zonder, J. A., & Dou, Q. P. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1268596 · Cited by 37 · see citing works
Characterization of DLBCL with a PMBL gene expression signature
Duns, G., Viganò, E., Ennishi, D., Sarkozy, C., Hung, S. S., Chavez, E. A., Takata, K., Rushton, C. K., Jiang, A., Ben‐Neriah, S., et al. (2021) · Blood · doi:10.1182/blood.2020007683 · Cited by 36 · see citing works
Self-citation
- Authors
- Rahal, R., Frick, M., Romero, R., Korn, J. M., Kridel, R., Chun Chan, F., Meissner, B., Bhang, H.-E., Ruddy, D., Kauffmann, A., Farsidjani, A., Derti, A., Rakiec, D., Naylor, T., Pfister, E., Kovats, S., Kim, S., Dietze, K., Dörken, B., Steidl, C., Tzankov, A., Hummel, M., Monahan, J., Morrissey, M. P., Fritsch, C., Sellers, W. R., Cooke, V. G., Gascoyne, R. D., Lenz, G., & Stegmeier, F.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- BC Cancer Agency (CA)
- Novartis Institutes for BioMedical Research (CH)
- University Hospital of Basel (CH)
- Corresponding author
- Lenz, Georg
- Stegmeier, Frank
- ORCID
- Venue
- Nature Medicine
- Published
- 2013-12-22
- Volume
- 20
- Issue
- 1
- Pages
- 87-92
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1977342543
- Cited by
- 334
- References
- 47
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 20 · 2023: 21 · 2022: 28 · 2021: 33 · 2020: 32 · 2019: 26 · 2018: 36 · 2017: 27 · 2016: 36 · 2015: 34 · 2014: 22
- FWCI
- 22.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- mantle cell lymphoma, NF-κB signaling, alternative NF-κB pathway, ibrutinib resistance, B cell receptor signaling, sotrastaurin, drug profiling, gene expression profiling, patient stratification, targeted therapy
- MeSH terms
- Baculoviral IAP Repeat-Containing 3 Protein, NF-kappaB-Inducing Kinase, Adenine, Base Sequence, Cell Line, Cell Survival, Guanylate Cyclase, Humans, Luminescent Measurements, Molecular Sequence Data, Piperidines, Pyrazoles, Pyrimidines, Pyrroles, Quinazolines, Receptors, Antigen, B-Cell, Trypan Blue, Blotting, Western, Signal Transduction, NF-kappa B, Protein Serine-Threonine Kinases, Sequence Analysis, RNA, DNA Primers, Lymphoma, Mantle-Cell, RNA Interference, Ubiquitin-Protein Ligases, Microarray Analysis, TNF Receptor-Associated Factor 2, TNF Receptor-Associated Factor 3, Inhibitor of Apoptosis Proteins, CARD Signaling Adaptor Proteins, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
